BIOSENSE WEBSTER INC CARTO VIZIGO¿ 8.5F BI-DIRECTIONAL GUIDING SHEATH ¿ SMALL; INTRODUCER, CATHETER
|
Back to Search Results |
|
Model Number D138501 |
Device Problems
Material Separation (1562); Obstruction of Flow (2423)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 01/01/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
(b)(6).The biosense webster, inc.Product analysis lab received the device for evaluation.The analysis has begun but is not completed at this time.When the investigational analysis has been completed, a supplemental 3500a report will be submitted.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's reference number: (b)(4).
|
|
Event Description
|
It was reported that a patient underwent an atrial fibrillation (afib) ablation procedure with a carto vizigo¿ 8.5f bi-directional guiding sheath ¿ small and a hemostatic valve separation issue occurred.It was not possible to insert the dilator into the sheath.Visible damage (displacement) of sheath's valve.The part that was separated was the transparent valve of the sheath, a white part (probably the entering part of the valve) was visible.It was probably pushed into the transparent part.The sheath was not used on the patient because of a complete block and the dilator was not insertable.Therefore, the sheath was not used on the patient.This sheath was replaced with another one and from the same type, so that procedure was ended successfully.There were no patient consequences.
|
|
Manufacturer Narrative
|
The device evaluation was completed on 11-mar-2022.It was reported that a patient underwent an atrial fibrillation (afib) ablation procedure with a carto vizigo¿ 8.5f bi-directional guiding sheath ¿ small and a hemostatic valve separation issue occurred.It was not possible to insert the dilator into the sheath.Visible damage (displacement) of sheath's valve.The part that was separated was the transparent valve of the sheath, a white part (probably the entering part of the valve) was visible.It was probably pushed into the transparent part.The sheath was not used on the patient because of a complete block and the dilator was not insertable.Therefore, the sheath was not used on the patient.This sheath was replaced with another one and from the same type, so that procedure was ended successfully.There were no patient consequences.Device evaluation details: the product was returned to biosense webster inc.(bwi) for evaluation.Bwi then conducted a visual inspection and microscopic examination of the returned device.Visual analysis of the returned sheath revealed that the hemostatic valve was not found on the hub component nor inside the sheath.The brim cap and silicone ring were found in normal condition.The vizigo¿ shaft was inspected, and it was found in normal condition.The dilator was found in normal condition.Microscopic examination showed that the silicone ring was placed in the correct position and found in good conditions.It should be noted that product failure is multifactorial.Based on the information currently available, the hemostatic valve could have been detached due to the dilator being wrongly introduced; however, this could not be conclusively determined since the valve was not returned for analysis.According to the odp (optimal performance guide), there are some precautions on inserting the dilator into the vizigo sheath: ¿always insert a dilator straight into the center of the sheath¿s valve to prevent damage to the valve.Do not insert a dilator at an angle, as damage to the sheath valve may occur.¿ the device history record (dhr) for the lot number 00001745 has been received and no internal actions related to the complaint were found during the review.As part of the quality process, all devices are manufactured, inspected, and released to approved specifications.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's reference number: (b)(4).
|
|
Manufacturer Narrative
|
If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's reference number: (b)(4) on 22-jan-2024, the h6.Investigation conclusions code was corrected from cause traced to user (d11) to unintended use error caused or contributed to event (d1102).
|
|
Search Alerts/Recalls
|
|
|